Email

bcalecyu@um.edu.mo

Tel

(853) 8822-8540

Office

N22-8008

Consultation Hours

Tue: 10:00~11:00
Wed: 10:00~11:00

Hua YU 余華

Associate Professor

Academic Qualifications

  • BSc., Pharmaceutics, China Pharmaceutical University, Nanjing China
  • MSc., Chinese Medicinal Sciences, University of Macau, Macao, China
  • MSc., Pharmacognosy, China Pharmaceutical University, Nanjing China
  • PhD., Biomedical Sciences, University of Macau, Macao, China

Teaching

HSCI1006Organic Chemistry LabUndergraduate Course
HSCI3010PharmaceuticsUndergraduate Course
HSCI3011Pharmaceutics LabUndergraduate Course
CMED7006Introduction to Research in Medical AdministrationM.Sc. Course
CMED7007Biomedical InformaticsM.Sc. Course
CMED8001Advanced PharmacokineticsPhD Course

Research Interests

Quality consistency assessment of traditional Chinese medicines

  • Chinese medicines for inflammatory diseases
  • Quality control and standards for Chinese medicines

Pharmaceutical Sciences

  • Innovative pharmaceutical designs and development
  • Functional polymeric nanoparticles for drug delivery

We are actively looking for high-caliber postdoctoral fellows, MSc and PhD students, as well as research assistants who are interested in Pharmaceutical Sciences, and/or Pharmacological Evaluation/Quality Control for Chinese Medicines. For further information, please contact Dr. Yu (bcalecyu@um.edu.mo).

Current Group Members

Postdoctoral

Linghu Kegang (2021- )                                 Zhang Tian (2021- )

PhD students

Zhao Mingming (2018-)                                 Chen Qiling (2019-)

Zhao Guanding (2020-)                                  Ma Qiushuo (2020-)

Xiong Shihang (2021-)

Master students  

Hua Tianyi (2019-)                                         Shen Liyu (2020-)

Yu Jinyu (2020-)                                             He Yu (2020-)

Xiao Linxuan (2021-)

Quality Research/Evaluation of Chinese medicines for inflammatory diseases

  1. Tao HX, Zhao GD, Linghu KG, Xiong W, Sang W, Peng Y, Wang YT, Yu H (*). Botany, traditional use, phytochemistry, pharmacology and toxicology of Sigesbeckiae Herba (Xixiancao): a review. Phytochem Rev. 2021, 20: 569-587. doi: 10.1007/s11101-020-09714-4.
  2. Zuo HL, Zhang QR, Chen C, Yang FQ, Yu H (*), Hu YJ (*). Molecular evidence of herbal formula: a network-based analysis of Si-Wu decoction. Phytochem Anal. 2021, 32(2): 198-205. doi: 10.1002/pca.2965.
  3. Yan YY, Guo QR, Wang FH, Adhikari R, Zhu ZY, Zhang HY, Zhou WM, Yu H (*), Li JQ (*), Zhang JY (*). Cell-Free DNA: Hope and Potential Application in Cancer. Front Cell Dev Biol. 2021, 9: 639233. doi: 10.3389/fcell.2021.639233.
  4. Luo H, Vong CT, Tan D, Zhang J, Yu H, Yang L, Zhang C, Luo C, Zhong Z (*), Wang Y (*). Panax notoginseng Saponins Modulate the Inflammatory Response and Improve IBD-Like Symptoms via TLR/NF-[Formula: see text]B and MAPK Signaling Pathways. Am J Chin Med. 2021, 49(4): 925-939. doi: 10.1142/S0192415X21500440.
  5. Vong CT, Tseng HHL, Yao P, Yu H, Wang S, Zhong Z (*), Wang Y (*). Specific NLRP3 inflammasome inhibitors: promising therapeutic agents for inflammatory diseases. Drug Discov Today. 2021, 26(6): 1394-1408. doi: 10.1016/j.drudis.2021.02.018.
  6. Linghu KG (†), Xiong SH (†), Zhao GD, Zhang T, Xiong W, Zhao M, Shen XC, Xu W, Bian Z, Wang Y, Yu H (*). Sigesbeckia orientalis Extract Alleviated the Collagen Type II-Induced Arthritis Through Inhibiting Multi-Target-Mediated Synovial Hyperplasia and Inflammation. Front Pharmacol. 2020, 11: 547913. doi: 10.3389/fphar.2020.547913.
  7. Ma QS (†), Linghu KG (†), Zhang T, Zhao GD, Xiong W, Xiong SH, Zhao M, Xu W, Yu J, Yu H (*). Sigesbeckia glabrescens Makino extract attenuated the collagen-induced arthritis through inhibiting the synovial hyperplasia and inflammation. Chin Med. 2020, 15: 91. doi: 10.1186/s13020-020-00372-4.
  8. Linghu KG (†), Zhao GD (†), Xiong W, Sang W, Xiong SH, Tse AKW, Hu Y, Bian Z, Wang Y, Yu H (*). Comprehensive comparison on the anti-inflammatory effects of three species of Sigesbeckia plants based on NF-κB and MAPKs signal pathways in vitro. J Ethnopharmacol. 2020, 250: 112530. doi: 10.1016/j.jep.2019.112530.
  9. Linghu KG, Ma QS, Zhao GD, Xiong W, Lin L, Zhang QW, Bian Z, Wang Y, Yu H (*). Leocarpinolide B attenuates LPS-induced inflammation on RAW264.7 macrophages by mediating NF-κB and Nrf2 pathways. Eur J Pharmacol. 2020, 868: 172854. doi: 10.1016/j.ejphar.2019.172854.
  10. Luo H (†), Zhao M (†), Tan D (†), Liu C, Yang L, Qiu L, Gao Y, Yu H (*). Anti-COVID-19 drug screening: Frontier concepts and core technologies. Chin Med. 2020, 15: 115. doi: 10.1186/s13020-020-00393-z.
  11. Chen YC, Huang MY, Zhang LL, Feng ZL, Jiang XM, Yuan LW, Huang RY, Liu B, Yu H, Wang YT, Chen XP, Lin LG, Lu JJ (*). Nagilactone E increases PD-L1 expression through activation of c-Jun in lung cancer cells. Chin J Nat Med. 2020, 18(7): 517-525. doi: 10.1016/S1875-5364(20)30062-5.
  12. Liu K, Zuo H, Li G, Yu H, Hu Y (*). Global research on artemisinin and its derivatives: Perspectives from patents. Pharmacol Res. 2020, 159:105048. doi: 10.1016/j.phrs.2020.105048.
  13. Li Q (†), Wang G (†), Xiong SH, Cao Y, Liu B, Sun J, Li L, Mohammadtursun N, Yu H, Dong J (*), Wu J (*). Bu-Shen-Fang-Chuan formula attenuates cigarette smoke-induced inflammation by modulating the PI3K/Akt-Nrf2 and NF-κB signalling pathways. J Ethnopharmacol. 2020, 261: 113095. doi: 10.1016/j.jep.2020.113095.
  14. Zuo HL, Linghu KG, Wang YL, Liu KM, Gao Y, Yu H, Yang FQ (*), Hu YJ (*). Interactions of antithrombotic herbal medicines with Western cardiovascular drugs. Pharmacol Res. 2020, 159: 104963. doi: 10.1016/j.phrs.2020.104963.
  15. Chen YJ (†), Zhu JQ (†), Fu XQ, Su T, Li T, Guo H, Zhu PL, Lee SK, Yu H, Tse AK (*), Yu ZL (*). Ribosome-Inactivating Protein α-Momorcharin Derived from Edible Plant Momordica charantia Induces Inflammatory Responses by Activating the NF-kappaB and JNK Pathways. Toxins (Basel). 2019, 11(12): 694. doi: 10.3390/toxins11120694.
  16. Wang Z (†), Linghu KG (†), Hu Y, Zuo H, Yi H, Xiong SH, Lu J, Chan G (*), Yu H (*), Huang RY. Deciphering the Pharmacological Mechanisms of the Huayu-Qiangshen-Tongbi Formula Through Integrating Network Pharmacology and In Vitro Pharmacological Investigation. Front Pharmacol. 2019, 10: 1065. doi: 10.3389/fphar.2019.01065.
  17. Li ZX, Zhao GD, Xiong W, Linghu KG, Ma QS, Cheang WS, Yu H (*), Wang Y (*). Immunomodulatory effects of a new whole ingredients extract from Astragalus: a combined evaluation on chemistry and pharmacology. Chin Med. 2019, 14: 12. doi: 10.1186/s13020-019-0234-0.
  18. Zhang QR (†), Zhong ZF (†), Sang W, Xiong W, Tao HX, Zhao GD, Li ZX, Ma QS, Tse AKW, Hu YJ (*), Yu H (*), Wang YT. Comparative comprehension on the anti-rheumatic Chinese herbal medicine Siegesbeckiae Herba: Combined computational predictions and experimental investigations. J Ethnopharmacol. 2019, 228: 200-209. doi: 10.1016/j.jep.2018.09.023.
  19. Wang Z (†), Lin HH (†), Linghu K, Huang RY, Li G, Zuo H, Yu H, Chan G (*), Hu Y (*). Novel Compound-Target Interactions Prediction for the Herbal Formula Hua-Yu-Qiang-Shen-Tong-Bi-Fang. Chem Pharm Bull (Tokyo). 2019, 67(8): 778-785. doi: 10.1248/cpb.c18-00808.
  20. Shen S, Yu H, Gan L, Ye Y, Lin L (*). Natural constituents from food sources: potential therapeutic agents against muscle wasting. Food Funct. 2019, 10(11): 6967-6986. doi: 10.1039/c9fo00912d.
  21. Zhong Z (†), Zhang Q (†), Tao H, Sang W, Cui L, Qiang W, Cheang WS, Hu Y (*), Yu H (*), Wang Y. Anti-inflammatory activities of Sigesbeckia glabrescens Makino: combined in vitro and in silico investigations. Chin Me 2019, 14:35. doi: 10.1186/s13020-019-0260-y.
  22. Li G, Zhou Y, Sze DM, Liu C, Zhang Q, Wang Z, Yu H, Chan G, Wu Z, Su S (*), Hu Y (*). Active Ingredients and Action Mechanisms of Yi Guan Jian Decoction in Chronic Hepatitis B Patients with Liver Fibrosis. Evid Based Complement Alternat Med. 2019, 2019: 2408126. doi: 10.1155/2019/2408126.
  23. Chen XM, Zhao Y, Wu XD, Wang MJ, Yu H, Lu JJ, Hu YJ, Huang QC, Huang RY (*), Lu CJ (*). Novel findings from determination of common expressed plasma exosomal microRNAs in patients with psoriatic arthritis, psoriasis vulgaris, rheumatoid arthritis, and gouty arthritis. Discov Med. 2019, 28(151): 47-68. PMID: 31465725.
  24. Linghu KG (†), Wu GP (†), Fu LY, Yang H, Li HZ, Chen Y, Yu H, Tao L (*), Shen XC (*). 1,8-Cineole Ameliorates LPS-Induced Vascular Endothelium Dysfunction in Mice via PPAR-γ Dependent Regulation of NF-κB. Front Pharmacol. 2019, 10: 178. doi: 10.3389/fphar.2019.00178.

Pharmaceutical Sciences

  1. Xiong W, Xiong SH, Chen QL, Linghu KG, Zhao GD, Chu JMT, Wong GTC, Li J, Hu YJ, Wang YT, Yu H (*). Brij-functionalized chitosan nanocarrier system enhances the intestinal permeability of P-glycoprotein substrate-like drugs. Carbohydr Polym. 2021, 266: 118112.
  2. Gao H (†), Su Y (†), Wang W (†), Xiong W, Sun X, Ji Y, Yu H (*), Li H (*), Ouyang D (*). Integrated computer-aided formulation design: A case study of andrographolide/ cyclodextrin ternary formulation. Asian Journal of Pharmaceutical Sciences. 2021, 16(4): 494-507. doi: 10.1016/j.ajps.2021.03.006.
  3. Luo K (†), Gao Y (†), Yin S, Yao Y, Yu H (*), Wang G, Li J (*). Co-delivery of paclitaxel and STAT3 siRNA by a multifunctional nanocomplex for targeted treatment of metastatic breast cancer. Acta Biomater. 2021, doi: 10.1016/j.actbio.2021.07.029.
  4. Zhang XJ (†), Gao QM (†), Zhuang QF (†), Zhang L (†), Wang SH, Du LB, Yuan WX, Wang CF, Tian Q, Yu H, Zhao YM (*), Liu Y. A dual-functional nanovehicle with fluorescent tracking and its targeted killing effects on hepatocellular carcinoma cells. RSC Advances. 2021, 11, 10986-10995. doi: 10.1039/d0ra10486h.
  5. Ma GL, Du X, Zhu JP, Xu F, Yu H, Li J (*). Multi-functionalized dendrimers for targeted co-delivery of sorafenib and paclitaxel in liver cancers. J Drug Deliv Sci Technol. 2021, doi: 10.1016/j.jddst.2021.102493.
  6. Luo KP, Lian YF, Zhang M, Yu H, Wang GJ, Li J (*). Charge convertible biomimetic micellar nanoparticles for enhanced melanoma-targeted therapy through tumor cells and tumor-associated macrophages dual chemotherapy with IDO immunotherapy. Chem Eng J. 2021, 412: 128659. doi: 10.1016/j.cej.2021.128659.
  7. Luo K (†), Xu F (†), Yao T, Zhu J, Yu H, Wang G, Li J (*). TPGS and chondroitin sulfate dual-modified lipid-albumin nanosystem for targeted delivery of chemotherapeutic agent against multidrug-resistant cancer. Int J Biol Macromol. 2021, 183: 1270-1282. doi: 10.1016/j.ijbiomac.2021.05.070. Epub 2021 May 15. PMID: 34004196.
  8. Luo K, Yin S, Zhang R, Yu H, Wang G, Li J (*). Multifunctional composite nanoparticles based on hyaluronic acid-paclitaxel conjugates for enhanced cancer therapy. Int J Pharm. 2020, 589: 119870. doi: 10.1016/j.ijpharm.2020.119870.
  9. Du X (†), Yin S (†), Xu L, Ma J, Yu H, Wang G, Li J (*). Polylysine and cysteine functionalized chitosan nanoparticle as an efficient platform for oral delivery of paclitaxel. Carbohydr Polym. 2020, 229: 115484. doi: 10.1016/j.carbpol.2019.115484.
  10. Gao HS, Ye ZYF, Dong J, Gao HL, Yu H, Li HF, Ouyang DF (*). Predicting drug/phospholipid complexation by the lightGBM method. Chem Phys Lett. 2020, 747: 137354. doi: org/10.1016/j.cplett.2020.137354.
  11. Xiong W, Zhao GD, Yin X, Linghu KG, Chu JMT, Wong GTC, Li H, Yu H (*), Wang YT. Brij-grafted-chitosan copolymers with function of P-glycoprotein modulation: Synthesis, characterization and in vitro Carbohydr Polym. 2019, 204: 89-96. doi: 10.1016/j.carbpol.2018.10.007.
  12. Zhao QQ, Gao HS, Su Y, Huang TH, Lu JH, Yu H, Ouyang DF (*). Experimental characterization and molecular dynamic simulation of ketoprofen-cyclodextrin complexes. Chem Phys Lett. 2019, 736: 136802. doi: 10.1016/j.cplett.2019.136802.

  • Yu H, Wang YT, Li ZX, Zhao GD. “Whole Ingredients System” herbal extract for healthcare, method of preparation and the use thereof. China, CN201811029369.X. 2018. (Granted)
  • Wang YT, LI P, Yu H, Wang CM, Wang SP, Zhang JM. Development of solid-liquid capsules for Chinese medicine. China, CN106963742A. 2016. (Granted)
  • Yu H, Lingu KG, Zhang CS, Zhang GT. Application of Deoxynyboquinone in preparation of anti-inflammatory drug or antioxidant drug. China, CN 202011461094.4. 2020. (Filed)
  • Yu H, Wang YT, Lingu KG, Zhao GD. New application of sesquiterpenoids. China, CN 201910964917.6. 2019. (Filed)
  • Yu H, Wang YT, Xiong W. A series of novel Brij-grafted-chitosan, method of preparation and the use thereof. China, CN 201811024505.6. 2018. (Filed)

  • Wang YT, Li P, Wan JB, Hu YJ, Yu H, Chen XJ, Wang SP, Zhong ZF, Luo H. 2020 International Award for Contribution to Chinese Medicine-Achievement Award in Medical Science (1st Prize) from World Federation of Chinese Medicine Societies. 2021-09.
  • Wang YT, Yu H, Wang CM, Li P, Wang SP, Lai CM, Zhang JM, Luo H, Li ZX, Gao CF, Zhao GD, Xiong W, Chen ZJ, Zhao MM, Linghu KG. Innovative Healthcare Products from Chinese Herbs. Gold Award of the 47th International Exhibition of Inventions of Geneva. 2019-04.
  • Zhao GD, Xiong SH, Ma QS, Zhao MM, Linghu KG, Xiong W, Yu H, Wang YT. A type of innovative granules for Chinese Medicines. Top 100 projects of the 2019 Competition of the high-valuable patents (Development and Layout) of Guangdong-Hong Kong-Macao Greater Bay Area. 2019-06.

  • Specialty Committee of Network Pharmacology of World Federation of Chinese Medicine Societies (WFCMS), Council Member
  • Specialty Committee of TCM Pharmaceutical of World Federation of Chinese Medicine Societies (WFCMS), Council Member
  • Precision Medicine Association of Macau, Committee Member
  • Macao Society of Supramolecular Chemistry and Biomaterials, Council Member
  • China Pharmaceutical University Hong Kong Alumni Association, Council Member
  • Editorial Board Member (Section Editor – Nanomedicine), Current Pharmaceutical Design, Bentham Science.
  • Editorial Board Member (Editor), International Journal of Pharmaceutical and Bio-Medical Science.
  • Editorial Board Member (Associate Editor), Virology & Immunology Journal (Medwin Publishers).
  • Editorial Board Member (Editor), International Journal of Traditional Medicine and Applications (Madridge Publishers).
  • Editorial Board Member (Editor), Acupuncture & Traditional Medicine (Henry publishing group).